British Journal of Haematology最新文献_第2页

Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland. 英国和爱尔兰儿科急性早幼粒细胞白血病的实际经验。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-17 DOI: 10.1111/bjh.19843

Aditi Vedi, Sarah Maria Leiter, Irum Latif Memon, Arunthethy Mahendrayogam, Elsje Van Rijswijk, Urmila Uparkar, Geoff Shenton, Amelie Trinquand, Katherine Clesham, Vanessa McLelland, Helen Campbell, Katharine Patrick, Lyndsey Thompson, Susan Baird, Philip Connor, Donna Lancaster, Beki James

引用次数: 0

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. 与 mRNA 疫苗相比，造血细胞移植受者接种 ChAdOx1-S (AZD1222) 疫苗后，SARS-CoV-2 中和抗体反应的保存率更高。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-17 DOI: 10.1111/bjh.19874

Hayley Colton, Natalie Barratt, Nigel Temperton, Hailey Hornsby, Adrienn Angyal, Irina Grouneva, Benjamin B Lindsey, Pamela Kearns, Eleanor Barnes, Carl S Goodyear, Alex Richter, David Thomas, Gordon Cook, Iain B McInnes, Michelle Willicombe, Stefan Siebert, Kim Orchard, Rachael Selby, Sarah Bowden, Paul J Collini, Ann Pope, Amanda Kirkham, Barbara Kronsteiner, Susanna J Dunachie, Paul Miller, Jennifer Clay, Erin Hurst, Ram Malladi, Murali Kesavan, Francesca Kinsella, Robin Sanderson, Kwee L Yong, Daniel Rea, Helen Parry, Sean H Lim, John A Snowden, Thushan I de Silva

{"title":"Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.","authors":"Hayley Colton, Natalie Barratt, Nigel Temperton, Hailey Hornsby, Adrienn Angyal, Irina Grouneva, Benjamin B Lindsey, Pamela Kearns, Eleanor Barnes, Carl S Goodyear, Alex Richter, David Thomas, Gordon Cook, Iain B McInnes, Michelle Willicombe, Stefan Siebert, Kim Orchard, Rachael Selby, Sarah Bowden, Paul J Collini, Ann Pope, Amanda Kirkham, Barbara Kronsteiner, Susanna J Dunachie, Paul Miller, Jennifer Clay, Erin Hurst, Ram Malladi, Murali Kesavan, Francesca Kinsella, Robin Sanderson, Kwee L Yong, Daniel Rea, Helen Parry, Sean H Lim, John A Snowden, Thushan I de Silva","doi":"10.1111/bjh.19874","DOIUrl":"https://doi.org/10.1111/bjh.19874","url":null,"abstract":"Whilst SARS-CoV-2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) recipients respond poorly. HSCT/CAR-T treatment ablates existing immune memory, with recipients requiring revaccination analogous to being vaccine naive. An optimal revaccination strategy for this cohort has not been defined. Factors predicting immunogenicity following three ancestral SARS-CoV-2 vaccines were assessed in 198 HSCT/CAR-T recipients and 96 healthcare workers (HCWs) recruited to multicentre studies. Only 25% of HSCT/CAR-T recipients generated nAbs following one dose, with titres 167-fold and 7-fold lower than that in HCWs after the first and second doses, respectively. Lower post-second dose nAb titres were associated with older age, rituximab use, and previous HSCT. ChAdOx1-S recipients were more likely to generate nAbs compared with mRNA vaccines, with titres comparable to HCWs. In contrast, nAbs were significantly lower in HSCT/CAR-T recipients than HCWs after mRNA vaccination. The poor first-dose immunogenicity in HSCT/CAR-T recipients suggests a minimum licensed dosing interval could limit the period of vulnerability following HSCT/CAR-T. The relative preservation of nAbs with ChAdOx1-S vaccination highlights the importance of evaluating alternative platforms to mRNA vaccination within this highly vulnerable clinical cohort.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of hydroxycarbamide treatment on the whole-blood transcriptome in sickle cell disease. 羟基甲酰胺治疗对镰状细胞病全血转录组的影响。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-17 DOI: 10.1111/bjh.19839

Varsha Bhat, Alka A Potdar, G Karen Yu, Greg Gibson, Vivien A Sheehan

{"title":"Impact of hydroxycarbamide treatment on the whole-blood transcriptome in sickle cell disease.","authors":"Varsha Bhat, Alka A Potdar, G Karen Yu, Greg Gibson, Vivien A Sheehan","doi":"10.1111/bjh.19839","DOIUrl":"https://doi.org/10.1111/bjh.19839","url":null,"abstract":"Hydroxycarbamide (HC) is the most widely used therapeutic for individuals with sickle cell disease (SCD, including sickle cell anemia and other forms of the disease). HC's clinical benefits are primarily associated with its ability to induce foetal haemoglobin (HbF); this limited view of HC's therapeutic potential may lead to its discontinuation when a modest amount of HbF is induced. A better understanding of the HbF-independent effects of HC on genes and pathways relevant to SCD pathophysiology is therefore needed. In this study, we performed bulk RNA-Seq on whole blood samples collected from a cohort of 25 paediatric patients with SCD to identify genes and pathways that are affected by treatment with HC. At the maximum tolerated dose (MTD) of HC, patients showed altered expression levels of several genes and biological pathways. Pathways related to haeme metabolism, interferon-alpha response, and interferon-gamma response were significantly downregulated at HC MTD relative to the matched pre-HC samples. Pathways linked with IL2-STAT5 signalling and TNFα signalling via NF-Kβ were observed to be up-regulated at HC MTD. These results illustrate the range of effects exerted by HC during therapy for SCD and pave the way for an improved understanding of the HbF induction-independent benefits of HC.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-14 DOI: 10.1111/bjh.19887

Giuseppe Bertuglia, Sara Bringhen, Benedetto Bruno, Giorgia Andrea Impalà, Mattia D'Agostino

引用次数: 0

Dutcher bodies and Russell bodies in a case of t(11;14) multiple myeloma. 一例 t（11;14）多发性骨髓瘤患者的 Dutcher 体和 Russell 体。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-14 DOI: 10.1111/bjh.19890

Jing Wu, Wei Cai, Mi Jiang

引用次数: 0

Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone. 剖析再生障碍性贫血后继发性骨髓增生异常综合征的基因组特征和临床过程：一个里程碑。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-14 DOI: 10.1111/bjh.19898

Carmelo Gurnari, Valeria Visconte

引用次数: 0

Clonal haemopoiesis and venous thromboembolism risk. 克隆性造血与静脉血栓栓塞风险。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-14 DOI: 10.1111/bjh.19893

David P Steensma

引用次数: 0

Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes. 骨髓增生异常综合征患者周围神经病变的临床和神经生理学方面。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-14 DOI: 10.1111/bjh.19901

Michail Papantoniou, Ioanna Stergiou, Stavroula Giannouli, Chrysanthi Bountziouka, Panagiotis Kokotis

引用次数: 0

Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia. 获得性再生障碍性贫血患者人类白细胞抗原 II 类分子上氨基酸多样性的比较研究。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-13 DOI: 10.1111/bjh.19899

Jun Qi, Tianju Wang, Manni Wang, Pengcheng He, Yuhui Li, Lixia Shang, Le Chen, Xiaofang Wang, Hua Xu, Chaofeng Ma

{"title":"Comparative study of the diversity of amino acids on human leucocyte antigen class II molecules in patients with acquired aplastic anaemia.","authors":"Jun Qi, Tianju Wang, Manni Wang, Pengcheng He, Yuhui Li, Lixia Shang, Le Chen, Xiaofang Wang, Hua Xu, Chaofeng Ma","doi":"10.1111/bjh.19899","DOIUrl":"https://doi.org/10.1111/bjh.19899","url":null,"abstract":"Human leucocyte antigen (HLA) class II molecules are critically involved in the pathology of acquired aplastic anaemia (AA) by regulating the immune response and autoreactive T cell-mediated haematopoietic cell death. In the study, amino acid residue variation and molecular structure of HLA class II have been initially investigated in 96 patients with AA. The frequencies of residues 9 and 57 in pocket 9 (P9) in DQB1, and amino acid positions 9, 11, 13, 16, 26, 38, 67 and 71 in the P4, P6 and P9 pockets in DRB1 were more prevalent among AA patients. By applying a multivariate recursive approach, the DRβ-Gln-16 (OR = 3.003, 95% CI = 1.468-6.145, pc = 0.003), DRβ-Ala-71 (OR = 1.924, 95% CI = 1.233-3.002, pc = 0.004) in P4/P7 and DQβ-Asp-57 (OR = 3.483, 95% CI = 1.079-11.242, pc = 0.037) in P9, these critical residues were significantly discovered as risk amino acid residues on the onset of AA, as well as associated with PNH-type cells and pathological somatic or cytogenetic mutations. In silico structural model analysis showed that identified DRβ-Ala-71 and DQβ-Asp-57 within the antigen-binding groove interacting with a more variable antigenic segments, may impact the repertoire of peptides presented, influence the interface HLA-antigen-T-cell receptor β (TCR β). These findings provided light on the immunogenetic pathophysiology of AA aetiology and their potential impact on upcoming immunotherapies.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free? 甲氨蝶呤和阿糖胞苷治疗成人 LCH：高风险、高回报、免维护？

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-13 DOI: 10.1111/bjh.19903

Jithma P Abeykoon, Ronald S Go, Levi-Dan Azoulay, Julien Haroche

引用次数: 0